

Index

A

ABCD rule, 10, 87, 89, 217
Acrokeratosis paraneoplastica, 180–181
Actinic keratoses (AK), 3–4, 12–14, 20–22, 51–56, 62, 63, 67, 69, 71, 151–153, 155, 156, 194, 215
Adjuvant radiation therapy, 114, 141, 144
Adjuvant treatment, 114, 163
AIDS, 31, 132–135, 155, 158, 160–162, 182, 192, 204
Anal cancer, 161, 166–167
Anogenital areas, 195
Atypical fibroxanthoma (AFX), 33, 138, 141–143
Atypical Spitz nevi, 173
Avoidance of tanning beds, 219–220

B

Basal cell carcinoma (BCC), 3, 5–7, 13, 17–20, 37–45, 53, 55, 57, 62, 90, 150, 153, 162, 168, 169, 174, 185, 186, 196–198, 206, 216
Bazex disease, 180–181
Behaviours, 214
Bowen's disease, 20, 21, 23, 56–57, 62, 63, 67, 71, 144, 167, 181–184
Breslow index, 113

C

CDK4, 83, 102
CDKN2A (*p16*), 83
Chemotherapy, 44, 45, 67, 73–75, 95, 97–102, 114–115, 124–127, 135, 144, 146, 152, 155, 159, 162, 163, 168, 170, 177, 184
Childhood UV-exposure, 174
Chronic antigen stimulation, 118, 160
Chronic inflammation, 65, 168, 170, 183, 195, 206
Chronic UV-exposure, 52, 112, 150, 152
Chronic UV-radiation, 152
CK 20, 30, 112
Classic Kaposi's sarcoma (KS), 170
Clinical evaluation, 1–4, 7, 123
Clinical indistinct features, 112–113
Congenital nevi, 2, 9, 174, 175
Cryotherapy, 41, 42, 54–55, 57, 67, 71, 75, 90, 152
Cutaneous T-cell lymphomas (CTCL), 117–121, 124–126, 161, 205
Cytology, 162, 165, 168

D

Denileukin diftitox, 100, 124, 125
Dermatofibrosarcoma protuberans, 32, 138–141, 177–178, 204
Dermoscopy, 6, 10–11, 53, 90, 187–189, 217, 218
Diagnosis/work-up, 40
Diclofenac in hyaluronic acid, 55–56, 153
Differential diagnosis, 3, 5, 7, 10, 19, 30, 56, 67, 90, 91, 134, 139, 142, 145, 153, 158, 170–171, 182–183, 189–190, 198, 204

E

Early diagnosis, 9, 113, 200, 220
Endemic KS, 132–133, 155
Epidemic KS, 132, 155, 158
Epstein-Barr virus (EBV), 118, 121, 160
Excisional biopsy, 10, 14, 70
Extramammary Paget's disease, 144–146, 170
Extremities, 64, 112, 114, 121, 122, 132, 133, 138, 141–143, 153, 176, 180, 195, 200, 201, 203

F

Family history, 2, 83, 86, 162, 175, 200, 213, 218, 220
Fibroepithelioma of Pinkus, 19
Field cancerization, 4, 52–55, 152

G

Genetics, 83
Genital area, 1, 56, 57, 86
Genital squamous cell carcinoma, 56, 57

H

High frequency ultrasound (HFUS), 11
High morbidity and mortality, 38, 114, 124, 192, 196, 205
High-risk-HPV types, 161, 166
Highly active antiretroviral therapy (HAART), 132, 133, 135, 158, 160–163
Histological analysis, 1
HIV-infection, 161, 162
HPV-vaccines, 162, 166
Human herpes virus 8 (HHV-8), 31, 118, 131–134, 155, 158, 160
Human papilloma viruses (HPV), 52, 56, 63, 66, 150–151, 161–162, 165–169, 182, 183, 195
Hutchinson sign, 182, 188, 189, 203

I

Iatrogenic KS, 132, 135, 155
 Imiquimod, 41, 44, 45, 55, 57, 67, 69, 71, 72, 74, 146, 152, 153, 162, 166, 167, 170, 183–184
 Immune response modifiers (IRMs)/Imiquimod, 44–45, 55
 Immunohistochemical staining, 20, 31, 32, 34, 122, 176
 Immunosuppression, 56, 68, 86, 132, 133, 135, 150–157, 200, 219
 Immunosuppressive medication, 132, 135, 150, 151
 Increasing incidence, 80
 Interferon-alpha, 73, 124, 125, 160, 163
 Intraepithelial neoplasia grade I-III, 53, 167

K

Kaposi's sarcoma, 31, 133, 155, 158–160, 163, 170

L

Locally aggressive growth, 138, 204
 Lymphoma, 30, 70, 112, 117–127, 132, 133, 143, 150, 160–161, 190, 205

M

Malignant fibrous histiocytoma, 34, 142–144
 Malignant melanoma, 9–10, 12, 13, 26–29, 79–103, 154–155, 168, 175, 176, 188, 189, 198, 215
 Managing skin cancer,
 Margins, 6, 10, 14, 41–43, 70–75, 90, 91, 93, 99, 102, 113–115, 122, 126, 133, 139–142, 144, 145, 152, 162, 163, 168–170, 175, 176, 178, 180, 183
 Melanoma, 9–10, 13, 26–29, 79–103, 154–155, 163, 169, 174–175, 187–191, 198–204, 218–219
 Melanoma types, 83–85
 Merkel cell carcinoma, 30, 67, 111–115, 153, 162, 205
 Metastatic melanoma, 97–103, 154
 Moh's micrographic surgery, 57
 Morpheaform basal cell carcinoma (BCC), 5, 19, 38, 39, 41, 43, 197, 198
 Most common skin cancer, 61, 153, 169, 194, 205, 206
 Multicentric neoplasm, 133
 Multidisciplinary approach, 113, 143, 152, 183
 Mycosis fungoides (MF), 118–120, 123–125, 205

N

Nail apparatus melanoma, 187–191
 Nodular basal cell carcinoma (NBCC), 19, 39, 42–45
 Non melanoma skin cancer (NMSC), 2, 12, 14, 37, 38, 42, 52, 61, 62, 71, 150, 151, 162, 189, 192, 193, 198, 212, 215, 216, 219, 220
 Non sun-exposed skin sites, 65, 79, 193–197, 200

O

Oncogenic proteins E6 and E7, 165
 Optical coherence tomography, 11–12

P

p53 mutations, 63, 198
 Penile cancer, 66, 162, 167–168
 Photodynamic therapy, 41–43, 54–55, 57, 67, 152, 170, 184, 186
 Prevention, 2, 56, 63, 67–69, 80, 150, 155, 162, 166, 174, 211–220

Primary cutaneous B-cell lymphomas (PCBCL), 118, 122–123, 126–127
 Primary prevention, 67, 162, 174, 212–216, 219, 220
 Pseudo-Hutchinson sign, 188
 Psoralen-UVA photochemotherapy (PUVA), 52, 68, 69, 124–126, 216
 PUVA. *See* Psoralen-UVA photochemotherapy

R

Radiation therapy, 42, 71, 97–99, 101, 114, 115, 141, 167–169, 184, 195, 197, 200
 Rare genital skin cancers, 165–171
 Rare skin cancers, 9, 19, 25–27, 38, 52, 90, 113, 118, 119, 122, 138, 143, 144, 153, 161, 167, 169–171, 174, 177, 178, 183, 185, 187–189, 193, 196–198, 204, 205
 Reduced UV-exposure, 213, 216
 Reflectance confocal microscopy (RCM), 4, 6–9, 12–13, 53
 Regular aftercare, 175
 Retinoids, 44, 55, 68, 69, 74, 75, 124–126, 135, 152, 153
 Risk assessment, 1–10
 Risk factors, 2, 40, 42, 52, 56, 62, 66, 67, 75, 76, 80, 82–84, 86, 111–112, 150–152, 154, 162, 167, 168, 174–176, 196–195, 197, 200, 201, 206, 212, 218, 219
 Rituximab, 126, 161

S

Secondary prevention, 80, 217–218, 220
 Sentinel lymph node biopsy (SLNB), 67, 70, 75, 91, 94–95, 113–115, 152, 162, 169, 176
 Sézary syndrome, 118, 120, 123–125, 161
 Skin cancer screenings, 2, 218
 Solid organ transplantation, 150
 Squamous cell carcinoma, 3–4, 13, 20–26, 51–57, 61–76, 84, 150–153, 162, 166, 168–169, 181–183, 186, 194–196, 206, 212, 215, 216
 Staging, 24, 70, 91, 92, 94, 96, 97, 99, 112, 113, 123–124, 154, 155, 158, 159, 168, 175
 Sun-exposed areas, 4, 5, 38, 52, 112, 193, 194, 196, 197, 200
 Sunburns in childhood, 87, 174, 200, 213, 214
 Sunscreen use, 67, 84, 155, 212–215
 Sunscreens, 56, 155–156, 213–215, 219, 220
 Superficial basal cell carcinoma (BCC), 5, 17, 39, 40, 42–45, 55, 57, 153, 186
 Surgical excision, 43–45, 54, 74, 75, 93, 95, 98, 99, 125, 126, 135, 144, 145, 166, 175, 177, 178
 Surgical treatment, 42, 43, 72, 73, 75, 93, 99, 115, 167, 183

T

Topical treatment, 55, 72, 159, 170, 183

U

Underlying malignancy, 145
 UV-radiation, 83, 162, 174

V

Verrucous carcinoma, 65–66, 151, 167, 182, 183
 Virus infection, 62, 90, 155
 Vulvar cancer, 168